Merck & Company Inc (MRK)vsXeris Pharmaceuticals Inc (XERS)
MRK
Merck & Company Inc
$119.60
+0.88%
HEALTHCARE · Cap: $283.78B
XERS
Xeris Pharmaceuticals Inc
$6.90
+0.49%
HEALTHCARE · Cap: $1.17B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 20788% more annual revenue ($65.77B vs $314.85M). MRK leads profitability with a 13.6% profit margin vs 3.8%. MRK trades at a lower P/E of 32.4x. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
XERS
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-40.6%
Fair Value
$80.96
Current Price
$119.60
$38.64 premium
Intrinsic value data unavailable for XERS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Revenue surging 38.3% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
3.8% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : XERS
The strongest argument for XERS centers on Revenue Growth. Revenue growth of 38.3% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : XERS
The primary concerns for XERS are EPS Growth, Market Cap, Profit Margin. A P/E of 97.0x leaves little room for execution misses. Debt-to-equity of 2.87 is elevated, increasing financial risk.
Key Dynamics to Monitor
MRK profiles as a value stock while XERS is a hypergrowth play — different risk/reward profiles.
XERS carries more volatility with a beta of 0.90 — expect wider price swings.
XERS is growing revenue faster at 38.3% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Xeris Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets ready-to-use injectable and infusible drug formulations. The company is headquartered in Chicago, Illinois.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?